Alzheimer's Disease — Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease
Citation(s)
A Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy of Oral AB1010 in Adults Patients With Mild to Moderate Alzheimer-type Disease.